Log in

NASDAQ:CORV - Correvio Pharma Stock Price, Forecast & News

$0.33
-0.02 (-5.65 %)
(As of 01/28/2020 07:36 AM ET)
Today's Range
$0.33
Now: $0.33
$0.36
50-Day Range
$0.33
MA: $0.44
$1.40
52-Week Range
$0.33
Now: $0.33
$4.44
Volume2.35 million shs
Average Volume3.31 million shs
Market Capitalization$18.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients, and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CORV
CUSIPN/A
CIKN/A
Phone604-677-6905

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.67 million
Book Value$0.19 per share

Profitability

Net Income$-16,580,000.00
Net Margins-121.25%

Miscellaneous

Employees163
Market Cap$18.50 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive CORV News and Ratings via Email

Sign-up to receive the latest news and ratings for CORV and its competitors with MarketBeat's FREE daily newsletter.


Correvio Pharma (NASDAQ:CORV) Frequently Asked Questions

What is Correvio Pharma's stock symbol?

Correvio Pharma trades on the NASDAQ under the ticker symbol "CORV."

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) released its quarterly earnings results on Thursday, November, 14th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.06. The business earned $6.67 million during the quarter, compared to analyst estimates of $8.87 million. Correvio Pharma had a negative return on equity of 1,022.22% and a negative net margin of 121.25%. View Correvio Pharma's Earnings History.

When is Correvio Pharma's next earnings date?

Correvio Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Correvio Pharma.

What price target have analysts set for CORV?

6 Wall Street analysts have issued 12 month price objectives for Correvio Pharma's stock. Their forecasts range from $1.60 to $7.00. On average, they expect Correvio Pharma's stock price to reach $5.40 in the next twelve months. This suggests a possible upside of 1,516.3% from the stock's current price. View Analyst Price Targets for Correvio Pharma.

What is the consensus analysts' recommendation for Correvio Pharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Correvio Pharma in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Correvio Pharma.

What are Wall Street analysts saying about Correvio Pharma stock?

Here are some recent quotes from research analysts about Correvio Pharma stock:
  • 1. According to Zacks Investment Research, "Correvio Pharma Corp. operates as a pharmaceutical company. It develops and discovers cardiovascular drugs for the treatment of atrial arrhythmia, congestive heart failure and bacterial skin infections. The company's product portfolio includes BRINAVESS(R), AGGRASTAT(R), ESMOCARD(R), ESMOCARDLYO(R), EXEMBOL(R) and XYDALBA(TM). Correvio Pharma Corp., formerly known as Correvio Pharma Corp., is based in Vancouver, Canada. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of Correvio and our 12-month price target of $10.50 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying a 4x multiple to our 2025 risk- adjusted revenue estimate discounted at 12%; and (2) price-earnings multiple analysis applying an 18x multiple to our 2025 estimated earnings discounted at 12%. (1) commercial; (2) clinical; (3) partnership; (4) financial; and (5) intellectual property." (3/15/2019)

Has Correvio Pharma been receiving favorable news coverage?

Media coverage about CORV stock has been trending somewhat negative on Tuesday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Correvio Pharma earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Correvio Pharma.

Are investors shorting Correvio Pharma?

Correvio Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,830,000 shares, an increase of 99.5% from the December 31st total of 917,300 shares. Based on an average trading volume of 2,790,000 shares, the short-interest ratio is currently 0.7 days. Approximately 3.7% of the company's shares are sold short. View Correvio Pharma's Current Options Chain.

Who are some of Correvio Pharma's key competitors?

What other stocks do shareholders of Correvio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Correvio Pharma investors own include Agile Therapeutics (AGRX), FuelCell Energy (FCEL), Acasti Pharma (ACST), AzurRx BioPharma (AZRX), Nabriva Therapeutics (NBRV), Aurora Cannabis (ACB), Biocept (BIOC), Onconova Therapeutics (ONTX), SCYNEXIS (SCYX) and Chesapeake Energy (CHK).

Who are Correvio Pharma's key executives?

Correvio Pharma's management team includes the folowing people:
  • Mark H. N. Corrigan, Chief Executive Officer & Director
  • Justin A. Renz, President & Chief Financial Officer
  • Sheila M. Grant, Chief Operating Officer
  • Hugues Sachot, Chief Commercial Officer
  • David Dean, Chief Business Development Officer

How do I buy shares of Correvio Pharma?

Shares of CORV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Correvio Pharma's stock price today?

One share of CORV stock can currently be purchased for approximately $0.33.

How big of a company is Correvio Pharma?

Correvio Pharma has a market capitalization of $18.50 million and generates $28.67 million in revenue each year. The company earns $-16,580,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Correvio Pharma employs 163 workers across the globe.View Additional Information About Correvio Pharma.

What is Correvio Pharma's official website?

The official website for Correvio Pharma is http://www.correvio.com/.

How can I contact Correvio Pharma?

Correvio Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The company can be reached via phone at 604-677-6905 or via email at [email protected]


MarketBeat Community Rating for Correvio Pharma (NASDAQ CORV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Correvio Pharma and other stocks. Vote "Outperform" if you believe CORV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Featured Article: What is the quiet period?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel